Amyotrophic Lateral Sclerosis — Amyotrophic Lateral Sclerosis and the Innate Immune System
Citation(s)
Andersen PM, Al-Chalabi A Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011 Oct 11;7(11):603-15. doi: 10.1038/nrneurol.2011.150. Review.
Annunziata P, Volpi N High levels of C3c in the cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neurol Scand. 1985 Jul;72(1):61-4.
Conradi S, Ronnevi LO Cytotoxic activity in the plasma of amyotrophic lateral sclerosis (ALS) patients against normal erythrocytes. Quantitative determinations. J Neurol Sci. 1985 May;68(2-3):135-45.
Conradi S, Ronnevi LO Immunoglobulin-mediated cytotoxic effect of ALS-plasma towards erythrocytes: reflexion of a pathogenetic mechanism? Adv Exp Med Biol. 1987;209:7-13.
Conradi, S Cytotoxic factor in plasma from ALS patients provokes haemolysis of normal erythrocytes. Acta Neurologica Scandinavica, 65: 246-247, 1982
Grewal RP, Morgan TE, Finch CE C1qB and clusterin mRNA increase in association with neurodegeneration in sporadic amyotrophic lateral sclerosis. Neurosci Lett. 1999 Aug 13;271(1):65-7.
Heurich B, El Idrissi NB, Donev RM, Petri S, Claus P, Neal J, Morgan BP, Ramaglia V Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. J Neuroimmunol. 2011 Jun;235(1-2):104-9. doi: 10.1016/j.jneuroim.2011.03.011. Epub 2011 Apr 17.
Kong J, Xu Z Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci. 1998 May 1;18(9):3241-50.
Liveson J, Frey H, Bornstein MB The effect of serum from ALS patients on organotypic nerve and muscle tissue cultures. Acta Neuropathol. 1975 Aug 11;32(2):127-31.
Lobsiger CS, Boillée S, Cleveland DW Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7319-26. Epub 2007 Apr 26.
Pun S, Santos AF, Saxena S, Xu L, Caroni P Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci. 2006 Mar;9(3):408-19. Epub 2006 Feb 12.
Ronnevi, LO , Conradi, S. and Karlsson, E. Cytotoxic effect of immunoglobulins in Amyotrophic Lateral Sclerosis (ALS). Acta Neurologica Scandinavica, 69: 182-183, 1984
Seals RM, Hansen J, Gredal O, Weisskopf MG Age-period-cohort analysis of trends in amyotrophic lateral sclerosis in Denmark, 1970-2009. Am J Epidemiol. 2013 Oct 15;178(8):1265-71. doi: 10.1093/aje/kwt116. Epub 2013 Sep 24.
Tsuboi Y, Yamada T Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1994 Jul;57(7):859-61.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.